PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity.
Immune Checkpoint Inhibitors
Immunotherapy
Natural Killer T-Cells
Receptors, Chimeric Antigen
Transplantation Immunology
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
31 Jan 2024
31 Jan 2024
Historique:
accepted:
21
12
2023
medline:
1
2
2024
pubmed:
1
2
2024
entrez:
31
1
2024
Statut:
epublish
Résumé
Relapse and graft-versus-host disease (GVHD) are the main causes of death after allogeneic hematopoietic cell transplantation (HCT). Preclinical murine models and clinical data suggest that invariant natural killer T (iNKT) cells prevent acute and chronic GVHD. In addition, iNKT cells are crucial for efficient immune responses against malignancies and contribute to reduced relapse rates after transplantation. Chimeric antigen receptors (CAR) redirect effector cells to cell surface antigens and enhance killing of target cells. With this study, we aimed to combine enhanced cytotoxicity of CD19-CAR-iNKT cells against lymphoma cells with their tolerogenic properties. iNKT cells were isolated from peripheral blood mononuclear cells and transduced with an anti-CD19-CAR retrovirus. After in vitro expansion, the functionality of CD19-CAR-iNKT cells was assessed by flow cytometry, image stream analysis and multiplex analysis in single-stimulation or repeated-stimulation assays. Moreover, the immunoregulatory properties of CD19-CAR-iNKT cells were analyzed in apoptosis assays and in mixed lymphocyte reactions. The effect of checkpoint inhibition through nivolumab was analyzed in these settings. In this study, we could show that the cytotoxicity of CD19-CAR-iNKT cells was mediated either through engagement of their CAR or their invariant T-cell receptor, which may circumvent loss of response through antigen escape. However, encounter of CD19-CAR-iNKT cells with their target induced a phenotype of exhaustion. Consequently, checkpoint inhibition increased cytokine release, cytotoxicity and survival of CD19-CAR-iNKT cells. Additionally, they showed robust suppression of alloreactive immune responses. In this work, we demonstrate that CAR-iNKT cells are a powerful cytotherapeutic option to prevent or treat relapse while potentially reducing the risk of GVHD after allogeneic HCT.
Sections du résumé
BACKGROUND
BACKGROUND
Relapse and graft-versus-host disease (GVHD) are the main causes of death after allogeneic hematopoietic cell transplantation (HCT). Preclinical murine models and clinical data suggest that invariant natural killer T (iNKT) cells prevent acute and chronic GVHD. In addition, iNKT cells are crucial for efficient immune responses against malignancies and contribute to reduced relapse rates after transplantation. Chimeric antigen receptors (CAR) redirect effector cells to cell surface antigens and enhance killing of target cells. With this study, we aimed to combine enhanced cytotoxicity of CD19-CAR-iNKT cells against lymphoma cells with their tolerogenic properties.
METHODS
METHODS
iNKT cells were isolated from peripheral blood mononuclear cells and transduced with an anti-CD19-CAR retrovirus. After in vitro expansion, the functionality of CD19-CAR-iNKT cells was assessed by flow cytometry, image stream analysis and multiplex analysis in single-stimulation or repeated-stimulation assays. Moreover, the immunoregulatory properties of CD19-CAR-iNKT cells were analyzed in apoptosis assays and in mixed lymphocyte reactions. The effect of checkpoint inhibition through nivolumab was analyzed in these settings.
RESULTS
RESULTS
In this study, we could show that the cytotoxicity of CD19-CAR-iNKT cells was mediated either through engagement of their CAR or their invariant T-cell receptor, which may circumvent loss of response through antigen escape. However, encounter of CD19-CAR-iNKT cells with their target induced a phenotype of exhaustion. Consequently, checkpoint inhibition increased cytokine release, cytotoxicity and survival of CD19-CAR-iNKT cells. Additionally, they showed robust suppression of alloreactive immune responses.
CONCLUSION
CONCLUSIONS
In this work, we demonstrate that CAR-iNKT cells are a powerful cytotherapeutic option to prevent or treat relapse while potentially reducing the risk of GVHD after allogeneic HCT.
Identifiants
pubmed: 38296597
pii: jitc-2023-007829
doi: 10.1136/jitc-2023-007829
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: No, there are no competing interests.
Références
Int J Mol Sci. 2021 Jan 22;22(3):
pubmed: 33499253
Haematologica. 2022 Feb 01;107(2):427-436
pubmed: 33440919
J Clin Invest. 2016 Aug 1;126(8):3130-44
pubmed: 27454297
Sci Rep. 2023 Jun 21;13(1):10082
pubmed: 37344517
Oncoimmunology. 2014 Dec 21;3(11):e970027
pubmed: 25941599
Blood. 2020 Jun 11;135(24):2182-2191
pubmed: 32478814
J Exp Med. 2011 Jun 6;208(6):1163-77
pubmed: 21555485
J Exp Med. 1994 Sep 1;180(3):1097-106
pubmed: 7520467
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Mol Ther. 2016 Jun;24(6):1135-1149
pubmed: 27019998
J Clin Invest. 2016 Jun 1;126(6):2341-55
pubmed: 27183388
Br J Haematol. 2021 Jan;192(1):212-216
pubmed: 33169845
Clin Cancer Res. 2021 Nov 1;27(21):6054-6064
pubmed: 34376537
J Immunol. 2008 Nov 15;181(10):6707-10
pubmed: 18981087
Br J Haematol. 2017 Nov;179(4):598-605
pubmed: 29076142
J Exp Med. 2000 Sep 4;192(5):741-54
pubmed: 10974039
Mol Ther. 2014 Jan;22(1):206-18
pubmed: 24196579
Blood Cancer J. 2021 Jun 4;11(6):108
pubmed: 34088894
J Exp Med. 1999 Apr 5;189(7):1073-81
pubmed: 10190898
Int J Cancer. 2019 Sep 1;145(5):1312-1324
pubmed: 30737788
Blood. 2016 Apr 7;127(14):1828-35
pubmed: 26903546
Immunol Rev. 2007 Dec;220:183-98
pubmed: 17979847
J Exp Med. 2007 Oct 29;204(11):2641-53
pubmed: 17923500
Blood. 2014 Nov 20;124(22):3320-8
pubmed: 25293774
Blood. 2014 Oct 30;124(18):2824-33
pubmed: 25049283
Sci Immunol. 2022 Aug 12;7(74):eabn6563
pubmed: 35984893
Cancer Immunol Immunother. 2015 Jul;64(7):817-29
pubmed: 25850344
Front Immunol. 2020 Oct 20;11:581301
pubmed: 33193386
J Immunol. 2001 Sep 15;167(6):3114-22
pubmed: 11544296
Blood. 2015 May 28;125(22):3491-500
pubmed: 25795920
J Immunol. 2001 Aug 15;167(4):2087-96
pubmed: 11489992
J Immunol. 2009 Mar 1;182(5):2816-26
pubmed: 19234176
Blood. 2012 Sep 6;120(10):2144-54
pubmed: 22730537
Cancer Cell. 2018 Oct 8;34(4):596-610.e11
pubmed: 30300581
J Immunother Cancer. 2022 Mar;10(3):
pubmed: 35246474
J Exp Med. 2003 Dec 1;198(11):1741-52
pubmed: 14657224
Immunity. 2007 Oct;27(4):597-609
pubmed: 17950005
Front Cell Dev Biol. 2020 Aug 18;8:803
pubmed: 32974346
Sci Transl Med. 2013 Aug 28;5(200):200ra116
pubmed: 23986400
J Hematol Oncol. 2017 Jan 31;10(1):35
pubmed: 28143567
N Engl J Med. 2016 Jul 14;375(2):143-53
pubmed: 27410923
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
J Exp Med. 1995 Dec 1;182(6):2091-6
pubmed: 7500054
Front Oncol. 2020 Sep 29;10:573822
pubmed: 33117709